VLA (ASX) 63 Million Shares traded since announcement

Originally posted by bripoz ↑

Hey 3rd door...
"Everybody on this forum seems to think the Merck are getting the company for a steal"
That's because they are!!
We are not happy about that!!
But it's the best we have right now... a bird in the hand.
Cavatak, to my mind, is also extremely valuable to BMS... in combination with their drug.
There is plenty of time for them to make a higher offer(very slim chance).... only BMS know their own intent.
If they don't .... then $1.75 is what we have on the table.
What would that do to Merck's resolve?

Try selling your house for what you think it's worth... good luck on that one!

If a "no" vote should get up(an unlikely eventuality)... I will be very dirty, so I will NOW consider exiting at sub $1.75 prior to the voting process....as I believe the SP will get closer to $1.75 , with time decay.
If a "no" vote should then succeed I will be a very interested bystander watching the SP drop significantly (a no brainer)... whilst the "no" vote smarties continue to "smart..." as time passes without any further offers forthcoming AND ... while alien Clinical Trial Results from other entities dribble onto the market.
But then the "no" voters will have enjoyed the satisfaction of not selling because Merck would have obtained Cavatak for a steal.... and they ("no" voters) will have triumphed in the pyrrhic war.

"I dont think this is the maximum Merck would be willing to pay for the technology."
Yes it is ... if there is no rival bid. Do you really think Merck are not across the whole scenario.... and certainly light years more advanced than VLA shareholders' understanding of the state of affairs?

"A no vote is not final it just says the offer on the table is too low."
Agreed!... however, the absence of a rival bid reinforces Merck's confidence not to increase their $1.75 offer.
Further, the VLA Board are in full support of the offer.
Ask yourself why.
Even a 50c/share increase in the offer would translate to substantial increases to their individual net worth
Put yourself in Merck's position .... would you offer more?

"I can only make an informed decision when all the information is available".
I guess "all the information" refers to the 'deadline for a rival bid' having passed .

Expand

IMHO, the voting - no or otherwise - by aussie retail investors aint worth a hill 'o beans in the grand scheme of things.

Instos will decide the future of this business.

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

HotCopper Highlights: Your most watched stocks for Week 48, 2024

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

MIN

63 Million Shares traded since announcement, page-36

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

63 Million Shares traded since announcement, page-36

Top Stories

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher